Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1002 in Advanced Solid Tumors
NCT04338724Phase 1Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CS1002 in solid tumor (advanced stage), sponsored by CStone Pharmaceuticals. Primary endpoints: clinical safety and tolerability, Area Under the Curve and 1 more. Started Dec 2019; status: completed.
02
Drugs
CS1002
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04338724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338724.